share_log

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8:員工福利計劃證券登記
美股sec公告 ·  04/19 00:36
牛牛AI助理已提取核心訊息
180 Life Sciences Corp., a biotechnology company based in Palo Alto, California, has filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on April 17, 2024. The filing is intended to register an additional 198,943 shares of the company's common stock under its 2022 Omnibus Incentive Plan, following an amendment that increased the number of shares reserved for issuance. This move comes after the company's previous filings on August 9, 2022, and August 30, 2023. The newly registered shares are designated for employee incentives, aiming to attract and retain talent by offering stock options and restricted stock. The registration incorporates by reference several of the company's previously filed SEC documents, including the Annual Report for the year ended December 31, 2023. The company's Chief Executive Officer, James N. Woody, has signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
180 Life Sciences Corp., a biotechnology company based in Palo Alto, California, has filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on April 17, 2024. The filing is intended to register an additional 198,943 shares of the company's common stock under its 2022 Omnibus Incentive Plan, following an amendment that increased the number of shares reserved for issuance. This move comes after the company's previous filings on August 9, 2022, and August 30, 2023. The newly registered shares are designated for employee incentives, aiming to attract and retain talent by offering stock options and restricted stock. The registration incorporates by reference several of the company's previously filed SEC documents, including the Annual Report for the year ended December 31, 2023. The company's Chief Executive Officer, James N. Woody, has signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
總部位於加利福尼亞州帕洛阿爾託的生物技術公司180 Life Sciences Corp. 已於2024年4月17日向美國證券交易委員會(SEC)提交了S-8表格的註冊聲明。該文件旨在根據其2022年綜合激勵計劃再註冊198,943股公司普通股,此前一項修正案增加了預留髮行的股票數量。此舉是在該公司先前於2022年8月9日和2023年8月30日提交申報之後採取的。新註冊的股票專門用於激勵員工,旨在通過提供股票期權和限制性股票來吸引和留住人才。該註冊以引用方式納入了該公司先前向美國證券交易委員會提交的幾份文件,包括截至2023年12月31日的年度報告。該公司首席執行官詹姆斯·伍迪簽署了註冊聲明,確認公司遵守了提交S-8表格的要求。
總部位於加利福尼亞州帕洛阿爾託的生物技術公司180 Life Sciences Corp. 已於2024年4月17日向美國證券交易委員會(SEC)提交了S-8表格的註冊聲明。該文件旨在根據其2022年綜合激勵計劃再註冊198,943股公司普通股,此前一項修正案增加了預留髮行的股票數量。此舉是在該公司先前於2022年8月9日和2023年8月30日提交申報之後採取的。新註冊的股票專門用於激勵員工,旨在通過提供股票期權和限制性股票來吸引和留住人才。該註冊以引用方式納入了該公司先前向美國證券交易委員會提交的幾份文件,包括截至2023年12月31日的年度報告。該公司首席執行官詹姆斯·伍迪簽署了註冊聲明,確認公司遵守了提交S-8表格的要求。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。